BIOTRON LIMITED — Investor Presentation 2017

Oct 5, 2017

==> picture [227 x 35] intentionally omitted <==

Level 2, 66 Hunter Street Sydney NSW 2000 Tel: (61-2) 9300 3344 Fax: (61-2) 9221 6333 E-mail: pnightingale@biotron.com.au Website: www.biotron.com.au

6 October 2017

The Manager Companies ASX Limited 20 Bridge Street Sydney NSW 2000

(15 pages by email)

Dear Madam

PRESENTATION TO INVESTORS

I attach a PowerPoint presentation as presented by Biotron Limited's Managing Director, Dr Michelle Miller, to investors.

Yours sincerely

==> picture [106 x 67] intentionally omitted <==

Peter J. Nightingale Company Secretary

pjn9101

BIOTRON LIMITED (ASX:BIT)

Investor Update October 2017

==> picture [720 x 66] intentionally omitted <==

results and business achievements/performance of Biotron Limited (ACN 086 399 144) and certain of the plans and objec4ves of its management. These statements are statements that are not historical facts. Words such as “should”, “expects”, “an4cipates”, “es4mates”, “believes” or similar expressions, as they relate to Biotron Limited, are intended to iden4fy forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect Biotron’s current expecta4ons and assump4ons as to future events and circumstances that may not prove accurate. There is no guarantee that the expected events, trends or results will actually occur. Any changes in such assump4ons or expecta4ons could cause actual results to differ materially from current expecta4ons.

==> picture [720 x 66] intentionally omitted <==

Biotron Limited - Investment Highlights

• Spun out from John Cur4n School of Medical Research at the Australian Na4onal University

• Listed on ASX (ASX:BIT)

• Headquartered in Sydney, Australia

Board

• Infec4ous disease focus

• Phase 2 clinical program - HIV-1 eradica4on trial data expected 4Q17

• Pipeline of earlier stage an4-viral programs including respiratory viruses, Dengue virus, hepa44s B virus and others

Michael Hoy Non-execu4ve Chairman Michelle Miller Managing Director Susan Pond Non-execu4ve Director Rob Thomas Non-execu4ve Director Denis Wade Non-execu4ve Director

• Several near term, value-adding milestones an4cipated over next few months

==> picture [720 x 66] intentionally omitted <==

• Exper4se is the development of a new class of an4viral drugs targe4ng viral-encoded viroporin proteins

• ~~Dengue and West Nile (M protein), SARS (E protein) and others~~

• Broad plaiorm:

• Rapid, proprietary primary bacterial cell-based screening assays for target proteins • Focused library of compounds that target these viral proteins

• for key markets

==> picture [720 x 66] intentionally omitted <==

• Small hydrophobic proteins with ion channel ac4vity

• Form hydrophilic pores in host cell membranes

~~• Key stages of the viral cycle suc~~ h as ~~virus uncoa4ng, transport and~~ matura4on are ion-influenced processes in many viral species ~~• Crucial for viral pathogenicity d~~ ue to ~~involvement in various steps of~~ virus life cycles • Ideal therapeu4c targets

Nature Reviews Microbiology 10 , 563-574

==> picture [720 x 66] intentionally omitted <==

HIV-1 EradicaEon

Current drugs do not eradicate HIV-1 virus

• HIV-1 remains hidden in reservoirs, leading to chronic, life-long infec4on

• Invisible to body’s immune defenses

• Not sensi4ve to an4-HIV-1 drugs

• New mode of ac4ons drugs are needed to eradicate or cure HIV-1 infec4on

Why is HIV-1 eradicaEon necessary?

• Long-term health implica4ons e.g. HAND, immune ac4va4on, etc

• Cost of treatment

• ~ $20 billion p.a. world wide

• Major burden on healthcare systems

Mario Stevenson Scien6fic American 299 , 78 - 83 (2008)

• BIT225 inhibits assembly and budding of new virus in macrophage reservoirs

• Phase 1b/2a trial (004) demonstrated that BIT225 can reduce HIV-1 levels in macrophage cells in vivo , paralleling in vitro studies (Wilkinson et al , J An4microb Chemother. 2015)

• above current anE-HIV drugs

==> picture [170 x 229] intentionally omitted <==

----- Start of picture text -----

A
----- End of picture text -----

==> picture [166 x 228] intentionally omitted <==

----- Start of picture text -----

B
----- End of picture text -----

==> picture [298 x 230] intentionally omitted <==

(A) Untreated Controls (B) BIT225 treated cells

Phase 2 Trial – BIT225-009 In Progress

==> picture [582 x 240] intentionally omitted <==

----- Start of picture text -----

BIT225 or placebo
added to ART
x
x x x x x x
----- End of picture text -----

• 36 HIV-1[+ve] , treatment-naïve subjects commencing ART

• Randomised 2:1 (drug:placebo)

• Read-out

• Impact on viral load kine4cs; reduc4on of immune ac4va4on markers

• Trial sites – HIV-NAT, Bangkok, and Chiang Mai, Thailand

• Fully recruited; preliminary data anEcipated Nov ‘17

==> picture [719 x 60] intentionally omitted <==

• Targets HCV p7 protein - Inhibits viral assembly and infec4vity

• Pan-genotype ac4vity:

• Ac4ve in vitro against all main genotypes

• Clinical ac4vity against HCV GT 1 (1a and 1b) and GT 3 demonstrated in Phase 2a trials

• Seeking partnerships for further development, in par4cular, in Asia

• Emerging evidence that Interferon sparing therapies may cause reac4va4on of Hepa44s B (HBV)

• Risk of reac4va4on of HBV has resulted in ‘black box’ warnings by the USA FDA on the recently approved HCV drugs

• 30 – 50 million HCV-infected subjects in China

  • High HCV/HBV co-infec4on rate in China

• popula4ons across emerging markets such as China; BIT225 well posi4oned for treatment of HCV in these popula4ons

Library of compounds designed to target viroporins: Ini4ally >250 compounds designed and synthesised; library now ~350

OTHER “HITS” IN LIBRARY include :

• Hepa44s B virus (HBV)

• Coronaviruses (Including SARS)

• Epstein-Barr virus (EBV)

• Zika virus

X-axis: compound ID Y-axis: virus Z-axis: strength of hit

• others

==> picture [720 x 66] intentionally omitted <==

• Renewed industry interest in targe4ng viral diseases including

• Hepa44s B virus

• Tropical diseases including Dengue

• worldwide

• BIT225 has demonstrated the robustness of Biotron’s approach with targeEng viroporin proteins

• screening is in progress, with the aim of iden4fying poten4al clinical candidates

• Main focus remains on commercialising the Company’s HIV-1 and HCV programs, but essen4al that other opportuni4es are developed

==> picture [720 x 66] intentionally omitted <==

CommercialisaEon: MulEple Partnering OpportuniEes

• ~~HIV-1 Program~~

• Aim to partner at conclusion of current Phase 2 trial

• HCV Program

• BIT225 par4cularly well suited to Asia, with high numbers of HCV-infected pa4ents including a high propor4on of HCV/HBV co-infected pa4ents

• Focused on achieving a regional deal for HCV in China in late 2017/early 2018

• Early stage collabora4on opportuni4es for pre-clinical targets, such as:

• Dengue

• Hepa44s B

• Addi4onal development collabora4on poten4al for “other” pharma targets

==> picture [720 x 66] intentionally omitted <==

Investment Highlights

NOVEL ANTIVIRAL PLATFORM

TargeEng viroporin proteins with a rapid screening proprietary primary bacterial cell-based pla`orm - a library of over 350 compounds with acEvity against a range of viruses.

BROAD ANTIVIRAL PIPELINE

Clinical and Preclinical programs in indicaEons with high unmet clinical need or large paEent populaEons such as HIV-1, HCV, Dengue, HBV, respiratory viruses, etc

ROBUST CLINICAL VALIDATION

outcomes; KEY PHASE 2 HIV-1 TRIAL DATA EXPECTED 4Q17

STRONG INTELLECTUAL Porolio of patents and patent applicaEons directed to the Company’s anEPROPERTY POSITION viral drug porolio

==> picture [719 x 60] intentionally omitted <==

==> picture [720 x 88] intentionally omitted <==

Dr Michelle Miller Managing Director +61 412 313329 mmiller@biotron.com.au www.biotron.com.au

15 20